

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/086385 A1

(51) International Patent Classification⁷: **A61K 31/341**,
31/40, 31/42, 31/433, 31/415, 31/4192, 31/4439, 31/404,
31/4709, 31/4427, 31/4196, 31/4162, 31/497, 31/427,
C07D 307/32, 207/26, 207/12, 413/06, 417/06, 403/12,
403/06, 407/06, 409/06, 401/06, 237/22

Box 13398, Research Triangle Park, NC 27709 (US).
SAMANO, Vicente [US/US]; c/o GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park, NC
27709 (US).

(21) International Application Number: PCT/US03/09893

(74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Corporate
Intellectual Property Dept, Five Moore Drive, PO Box
13398, Research Triangle Park, NC 27709 (US).

(22) International Filing Date: 1 April 2003 (01.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/371,524 10 April 2002 (10.04.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, Philadelphia, PA 19101
(US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BARRETT,
David, Gene [US/DE]; Elsa-Brandstrom-Stieg 2, 22846
Norderstedt (DE). CATALANO, John, G. [US/US]; c/o
GlaxoSmithKline, Five Moore Drive, PO Box 13398,
Research Triangle Park, NC 27709 (US). DEATON,
David, Norman [US/US]; c/o GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park,
NC 27709 (US). MILLER, Aaron, Bayne [US/US]; c/o
GlaxoSmithKline, Five Moore Drive, PO Box 13398,
Research Triangle Park, NC 27709 (US). RAY, John, A
[US/US]; c/o GlaxoSmithKline, Five Moore Drive, PO

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guidance
Notes on Codes and Abbreviations" appearing at the beginning
of each regular issue of the PCT Gazette.*

(54) Title: DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYL CARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS

(57) Abstract: Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, Z and R are defined as in claim 1, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as methods of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.

WO 03/086385 A1